Bio-Thera Solutions Joins Forces with Tabuk Pharmaceuticals to Launch BAT2206, a Biosimilar to Stelara®, in Saudi Arabia

Guangzhou, China – Bio-Thera Solutions Inc. (688177:SH), a global leader in biopharmaceutical innovation and biosimilars, has entered a strategic partnership with Tabuk Pharmaceutical Manufacturing Company, a prominent pharmaceutical powerhouse in the Middle East and North Africa (MENA) region. This collaboration will bring BAT2206, Bio-Thera’s proposed biosimilar to Stelara® (ustekinumab), to Saudi Arabia, marking a significant milestone in expanding access to advanced therapies.

Under the agreement, Tabuk Pharmaceuticals, a fully-owned subsidiary of Astra Industrial Group, will exclusively handle the manufacturing, distribution, and commercialization of BAT2206 in Saudi Arabia. Bio-Thera will focus on its core strengths—overseeing development and ensuring commercial supply from its cutting-edge facilities in Guangzhou, China.

“We are thrilled to partner with Tabuk Pharmaceuticals to bring BAT2206 to patients in Saudi Arabia,” said Dr. Shengfeng Li, CEO of Bio-Thera Solutions. “Tabuk’s unparalleled market expertise and robust presence in the MENA region make them the ideal partner to ensure access to this critical biosimilar therapy.”

Ismail Shehada, CEO of Tabuk Pharmaceuticals, echoed this sentiment: “This partnership reflects our commitment to enhancing healthcare solutions in Saudi Arabia and aligns with the Kingdom’s Vision 2030 initiative to localize biopharmaceutical manufacturing. We look forward to providing patients with affordable, high-quality treatment options while strengthening our leadership in the region.”

This collaboration between the two giants leverages Tabuk’s well-established infrastructure and commercial acumen in the Saudi market. As the holder of the marketing authorization, Tabuk will manage the entire lifecycle of BAT2206 in the Kingdom, from registration to promotion and patient outreach. Together, the companies aim to enhance treatment accessibility while addressing unmet healthcare needs in the region.